Q2 2026 saw 16% net sales growth at constant currency, led by BD recovery and record Wound Management results. Adjusted EBITDA improved, and a new global BD agreement was signed. Management maintains a positive outlook with continued double-digit growth expected in Wound Management.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.